Palivizumab injection is used to prevent serious lung infection in children and babies caused by respiratory syncytial virus ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

Chinese regulators are investigating the quality of domestic generic drugs after a rare public backlash against a cost-cutting campaign that prioritised their use in the national healthcare system but ...

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...

A small proportion of veterans who went from a metered-dose inhaler to a dry-powder inhaler had to revert to the metered-dose ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...

The first-in class medicine for severe asthma co-developed by AstraZeneca and Amgen is poised for accelerated approval after the US Food and Drug Administration granted it a breakthrough designation.

Listed Tyneside pharmaceutical firm Shield Therapeutics has appointed a new CEO. The Gateshead drug discovery business, which ...

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...